This site is intended for healthcare professionals

AT 527, an oral antiviral reduces viral replication in hospitalized patients with COVID-19 in phase II interim analysis. Atea + Roche

Read time: 2 mins
Last updated:29th Jul 2021
Published:4th Jul 2021
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, announced positive interim results from the global Phase II study evaluating AT 527 in hospitalized patients with mild-to-moderate COVID-19. Roche and Atea are jointly developing AT 527, an oral direct-acting antiviral (DAA) agent derived from Atea’s purine nucleotide prodrug platform.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest